Obalon Therapeutics, Inc. (OBLN): Price and Financial Metrics


Obalon Therapeutics, Inc. (OBLN)

Today's Latest Price: $1.16 USD

0.21 (22.11%)

Updated Dec 2 4:00pm

Add OBLN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

OBLN Stock Summary

  • With a market capitalization of $7,382,163, Obalon Therapeutics Inc has a greater market value than merely 3.36% of US stocks.
  • The ratio of debt to operating expenses for Obalon Therapeutics Inc is higher than it is for about just 11.48% of US stocks.
  • As for revenue growth, note that OBLN's revenue has grown -48.92% over the past 12 months; that beats the revenue growth of just 5.28% of US companies in our set.
  • Stocks that are quantitatively similar to OBLN, based on their financial statements, market capitalization, and price volatility, are XXII, LEAF, FLDM, APDN, and CTSO.
  • OBLN's SEC filings can be seen here. And to visit Obalon Therapeutics Inc's official web site, go to www.obalon.com.

OBLN Stock Price Chart Interactive Chart >

Price chart for OBLN

OBLN Price/Volume Stats

Current price $1.16 52-week high $2.14
Prev. close $0.95 52-week low $0.62
Day low $0.94 Volume 13,750,125
Day high $1.65 Avg. volume 401,494
50-day MA $0.91 Dividend yield N/A
200-day MA $0.89 Market Cap 9.01M

Obalon Therapeutics, Inc. (OBLN) Company Bio


Obalon Therapeutics, a commercial-stage medical device company, focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. It offers the Obalon balloon system designed to provide weight loss in obese patients. The company was founded in 2008 and is based in Carlsbad, California.


OBLN Latest News Stream


Event/Time News Detail
Loading, please wait...

OBLN Latest Social Stream


Loading social stream, please wait...

View Full OBLN Social Stream

Latest OBLN News From Around the Web

Below are the latest news stories about Obalon Therapeutics Inc that investors may wish to consider to help them evaluate OBLN as an investment opportunity.

Obalon Announces Second Quarter 2020 Financial Results

SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced its financial results for the second quarter ended June 30, 2020. Financial results for the second quarter of 2020Revenue for the second quarter of 2020 was $0.7 million, compared to $0.4 million for the second quarter of 2019, primarily due to reversals of revenue reserves as a result of suspending business operations at the company-branded retail treatment centers. Net loss for the second quarter of 2020 was $4.2 million, compared to $6.8 million for the second quarter of 2019. Net loss per share for the second quart...

Yahoo | July 30, 2020

Obalon Therapeutics EPS misses by $0.17, beats on revenue

Obalon Therapeutics (OBLN): Q1 GAAP EPS of -$0.68 misses by $0.17.Revenue of $0.78M (-56.2% Y/Y) beats by $0.08M.Press Release...

Seeking Alpha | June 19, 2020

Obalon's retail treatment centers to remain shut; delays shipments

Obalon Therapeutics (OBLN) provides business updates.Citing COVID-19 uncertainties and its economic impact, the Company does not currently plan to re-open its retail treatment centers, re-initiate its retail treatment center expansion plans, or plan to ship orders to U.S. customers or its international distributor.As a result, Obalon does not expect to...

Seeking Alpha | June 19, 2020

Obalon Announces First Quarter 2020 Financial Results and Business Update

SAN DIEGO, June 19, 2020 -- Obalon Therapeutics, Inc. (Nasdaq: OBLN), a weight loss solutions company with the first and only FDA-approved swallowable, gas-filled intragastric.

Yahoo | June 19, 2020

Obalon Announces Further Impacts Related To Covid-19 Crisis and Current Business Environment

Obalon Therapeutics, Inc. (“Obalon” or the “Company”) (NASDAQ:OBLN), a vertically integrated weight loss solutions company commercializing the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, announces changes related to the impacts of the Covid-19 crisis and current business environment on its business, organization and strategic options. As previously announced, the overall uncertainty, the restriction on elective procedures and the specific directives issued by the Governor of California as a result of Covid-19 have had a significant impact on Obalon’s business. In March, the Company halted sales to new patients in its company-branded retail treatment centers and expansion plans for additional retail centers, which was pa...

Yahoo | May 11, 2020

Read More 'OBLN' Stories Here

OBLN Price Returns

1-mo 17.65%
3-mo 48.02%
6-mo 14.29%
1-year -36.96%
3-year -98.59%
5-year N/A
YTD -38.95%
2019 -90.82%
2018 -68.68%
2017 -25.31%
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.792 seconds.